中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞性肝癌患者介入治疗前后血清蛋白质组的变化

师越 李悦国

汪毅, 余贻汉, 屈银宗, 郭玉飞, 计春燕, 吴勇进, 徐玲. 腹腔置管治疗顽固性腹水对血浆RAAS的影响[J]. 临床肝胆病杂志, 2009, 25(2): 131-132.
引用本文: 汪毅, 余贻汉, 屈银宗, 郭玉飞, 计春燕, 吴勇进, 徐玲. 腹腔置管治疗顽固性腹水对血浆RAAS的影响[J]. 临床肝胆病杂志, 2009, 25(2): 131-132.
Wang Yi, Yu YiHan, Qu YinZong, Guo YuFei, Ji ChunYan, Wu YongJin, Xu Ling. Effects of percutaneous placement of central venous catheter on RAAS in hepatic cirrhosis patients with refractory ascites[J]. J Clin Hepatol, 2009, 25(2): 131-132.
Citation: Wang Yi, Yu YiHan, Qu YinZong, Guo YuFei, Ji ChunYan, Wu YongJin, Xu Ling. Effects of percutaneous placement of central venous catheter on RAAS in hepatic cirrhosis patients with refractory ascites[J]. J Clin Hepatol, 2009, 25(2): 131-132.

肝细胞性肝癌患者介入治疗前后血清蛋白质组的变化

详细信息
  • 中图分类号: R735.7

Detection and evaluation of serum proteomic patters for hepatocellular carcinoma treated by interventional therapy Using SELDI-TOF-MS protein chip array

  • 摘要: 目的用表面增强激光解吸离子化飞行时间质谱(surface-enhanced laser desorption-ionization timeof-flight mass spectrometry,SELDI-TOF-MS)蛋白质芯片检测肝细胞性肝癌(简称肝癌)患者介入治疗前后血清蛋白质组的变化,初步探讨肝癌介入治疗的药物靶点。方法应用SELDI-TOF-MS蛋白质芯片检测50例未经治疗的肝癌患者、50例介入治疗的肝癌患者,获得弱阳离子交换芯片(weak cationic exchanger)蛋白表达图谱,Bio-Marker Wizard软件分析差异蛋白。结果未经治疗的肝癌患者和介入治疗的肝癌患者血清中检测到不同质荷比处有3个差异蛋白质峰,其蛋白质含量差异有统计学意义(P<0.05)。数据库搜索这3个蛋白质峰,得到3种与之分子量最为接近的蛋白质。结论应用SELDI-TOF-MS筛选肝癌患者介入治疗的药物靶点快速、有效,检测到的3个差异蛋白质可能是肝癌患者介入治疗的药物靶点。

     

  • [1]Schwegler EE, Cazares L, Steel LF, et al.SELDI-TOF MS profi-ling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma[J].Hepatology, 2005, 41∶634-642.
    [1]Schwegler EE, Cazares L, Steel LF, et al.SELDI-TOF MS profi-ling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma[J].Hepatology, 2005, 41∶634-642.
    [2]Paradis V, Degos F, Dargere D, et al.Identification of a newmarker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver disease[J].Hepatology, 2005, 41∶40-47.
    [2]Paradis V, Degos F, Dargere D, et al.Identification of a newmarker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver disease[J].Hepatology, 2005, 41∶40-47.
    [3]Roelofsen H, Balgobind R, Vonk RJ.Proteomic analyzes of copper metabolism in an in vitro model of Wilson disease using surface en-hanced laser desorption/ionization-time of flight-mass spectrome-try[J].J Cell Biochem, 2004, 93∶732-740.
    [3]Roelofsen H, Balgobind R, Vonk RJ.Proteomic analyzes of copper metabolism in an in vitro model of Wilson disease using surface en-hanced laser desorption/ionization-time of flight-mass spectrome-try[J].J Cell Biochem, 2004, 93∶732-740.
    [4]汤钊猷.现代肿瘤学[M].上海:上海医科大学出版社, 1993∶561.
    [4]汤钊猷.现代肿瘤学[M].上海:上海医科大学出版社, 1993∶561.
    [5]Parasole R, Izzo F, Perrone F, et al.Prognostic value of serum bio-logical markers in patients with hepatocellular carcinoma[J].Clin Cancer Res, 2001, 7∶3504-3509.
    [5]Parasole R, Izzo F, Perrone F, et al.Prognostic value of serum bio-logical markers in patients with hepatocellular carcinoma[J].Clin Cancer Res, 2001, 7∶3504-3509.
    [6]李悦国, 张维铭.蛋白质组学在肝癌及其相关疾病研究中的应用[J].中国肿瘤临床, 2005, 32∶957-960.
    [6]李悦国, 张维铭.蛋白质组学在肝癌及其相关疾病研究中的应用[J].中国肿瘤临床, 2005, 32∶957-960.
    [7]Wu W, Hu W, Kavanagh JJ.Proteomics in cancer research[J].Int J Gynecol Cancer, 2002, 12∶409-423.
    [7]Wu W, Hu W, Kavanagh JJ.Proteomics in cancer research[J].Int J Gynecol Cancer, 2002, 12∶409-423.
    [8]Lueking A, Cahill DJ, Mullner S.Protein biochips:A newand ver-satile platform technology for molecular medicine[J].Drug Discov Today, 2005, 10∶789-794.
    [8]Lueking A, Cahill DJ, Mullner S.Protein biochips:A newand ver-satile platform technology for molecular medicine[J].Drug Discov Today, 2005, 10∶789-794.
    [9]Figeys D, Pinto D.Proteomics on a chip:promising developments[J].Electrophoresis, 2001, 22∶208-216.
    [9]Figeys D, Pinto D.Proteomics on a chip:promising developments[J].Electrophoresis, 2001, 22∶208-216.
    [10]Issaq HJ, Veenstra TD, Conrads TP, et al.The SELDI-TOF MS ap-proach to proteomics:protein profiling and biomarker identification[J].Biochem Biophys Res Commun, 2002, 292∶587-592.
    [10]Issaq HJ, Veenstra TD, Conrads TP, et al.The SELDI-TOF MS ap-proach to proteomics:protein profiling and biomarker identification[J].Biochem Biophys Res Commun, 2002, 292∶587-592.
    [11]Petricoin EF, Ardekani AM, Hitt BA, et al.Use of proteomic pat-terns in serum to identify ovarian cancer[J].Lancet, 2002, 359∶572.
    [11]Petricoin EF, Ardekani AM, Hitt BA, et al.Use of proteomic pat-terns in serum to identify ovarian cancer[J].Lancet, 2002, 359∶572.
    [12]Adam BL, Qu Y, Davis JW, et al.Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from algorithm distinguishes prostate cancer from benign pros-tate hyperplasia and healthy men[J].Cancer Res, 2002, 62∶3609.
    [12]Adam BL, Qu Y, Davis JW, et al.Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from algorithm distinguishes prostate cancer from benign pros-tate hyperplasia and healthy men[J].Cancer Res, 2002, 62∶3609.
  • 加载中
计量
  • 文章访问数:  2266
  • HTML全文浏览量:  21
  • PDF下载量:  831
  • 被引次数: 0
出版历程
  • 出版日期:  2009-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回